1. Home
  2. IMCR vs SRPT Comparison

IMCR vs SRPT Comparison

Compare IMCR & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • SRPT
  • Stock Information
  • Founded
  • IMCR 2008
  • SRPT 1980
  • Country
  • IMCR United Kingdom
  • SRPT United States
  • Employees
  • IMCR N/A
  • SRPT N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • SRPT Biotechnology: Pharmaceutical Preparations
  • Sector
  • IMCR Health Care
  • SRPT Health Care
  • Exchange
  • IMCR Nasdaq
  • SRPT Nasdaq
  • Market Cap
  • IMCR 1.8B
  • SRPT 1.7B
  • IPO Year
  • IMCR 2021
  • SRPT 1997
  • Fundamental
  • Price
  • IMCR $33.38
  • SRPT $20.83
  • Analyst Decision
  • IMCR Buy
  • SRPT Hold
  • Analyst Count
  • IMCR 10
  • SRPT 29
  • Target Price
  • IMCR $58.13
  • SRPT $46.15
  • AVG Volume (30 Days)
  • IMCR 315.0K
  • SRPT 22.8M
  • Earning Date
  • IMCR 08-07-2025
  • SRPT 08-06-2025
  • Dividend Yield
  • IMCR N/A
  • SRPT N/A
  • EPS Growth
  • IMCR N/A
  • SRPT N/A
  • EPS
  • IMCR N/A
  • SRPT N/A
  • Revenue
  • IMCR $356,145,000.00
  • SRPT $2,481,531,000.00
  • Revenue This Year
  • IMCR $27.43
  • SRPT $3.52
  • Revenue Next Year
  • IMCR $8.64
  • SRPT N/A
  • P/E Ratio
  • IMCR N/A
  • SRPT N/A
  • Revenue Growth
  • IMCR 26.78
  • SRPT 64.89
  • 52 Week Low
  • IMCR $23.15
  • SRPT $10.42
  • 52 Week High
  • IMCR $39.33
  • SRPT $144.22
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 49.64
  • SRPT 57.32
  • Support Level
  • IMCR $31.02
  • SRPT $17.28
  • Resistance Level
  • IMCR $33.73
  • SRPT $20.61
  • Average True Range (ATR)
  • IMCR 1.49
  • SRPT 1.51
  • MACD
  • IMCR -0.03
  • SRPT 0.96
  • Stochastic Oscillator
  • IMCR 44.61
  • SRPT 95.91

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.

Share on Social Networks: